Strategies for replacing myocytes with induced pluripotent stem in clinical protocols

Fumiyuki Hattori, Keiichi Fukuda

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Induced pluripotent stem (iPS) cells can be established via forced epigenetic reprogramming of various somatic cells and selection based on given criteria. Human iPS cells are preferred for clinical applications because they present fewer ethical concerns than embryonic stem cells. However, technical issues of stability and safety must be fully validated before clinical use. Moreover, heart regenerative therapies would require approximately 109 cardiomyocytes per person, necessitating the following technical considerations: (1) genetically and epigenetically stable scaling up of the iPS cells, (2) efficient and reproducible differentiation, and (3) highly reliable cell purification. Furthermore, (4) strategies for efficient iPS transplantation, rapid maturation, and functional integration of grafted cardiomyocytes into the host myocardium are critical unmet technologies. Herein, we discuss current progress and unmet problems for the realization of heart regenerative therapy.

Original languageEnglish
Pages (from-to)223-232
Number of pages10
JournalTransplantation Reviews
Volume26
Issue number3
DOIs
Publication statusPublished - 2012 Jul

Fingerprint

Induced Pluripotent Stem Cells
Clinical Protocols
Muscle Cells
Cardiac Myocytes
Embryonic Stem Cells
Epigenomics
Myocardium
Transplantation
Technology
Safety
Therapeutics

ASJC Scopus subject areas

  • Transplantation

Cite this

Strategies for replacing myocytes with induced pluripotent stem in clinical protocols. / Hattori, Fumiyuki; Fukuda, Keiichi.

In: Transplantation Reviews, Vol. 26, No. 3, 07.2012, p. 223-232.

Research output: Contribution to journalArticle

@article{45a519487a4a45e7ba88908245e152ef,
title = "Strategies for replacing myocytes with induced pluripotent stem in clinical protocols",
abstract = "Induced pluripotent stem (iPS) cells can be established via forced epigenetic reprogramming of various somatic cells and selection based on given criteria. Human iPS cells are preferred for clinical applications because they present fewer ethical concerns than embryonic stem cells. However, technical issues of stability and safety must be fully validated before clinical use. Moreover, heart regenerative therapies would require approximately 109 cardiomyocytes per person, necessitating the following technical considerations: (1) genetically and epigenetically stable scaling up of the iPS cells, (2) efficient and reproducible differentiation, and (3) highly reliable cell purification. Furthermore, (4) strategies for efficient iPS transplantation, rapid maturation, and functional integration of grafted cardiomyocytes into the host myocardium are critical unmet technologies. Herein, we discuss current progress and unmet problems for the realization of heart regenerative therapy.",
author = "Fumiyuki Hattori and Keiichi Fukuda",
year = "2012",
month = "7",
doi = "10.1016/j.trre.2011.09.003",
language = "English",
volume = "26",
pages = "223--232",
journal = "Transplantation Reviews",
issn = "0955-470X",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Strategies for replacing myocytes with induced pluripotent stem in clinical protocols

AU - Hattori, Fumiyuki

AU - Fukuda, Keiichi

PY - 2012/7

Y1 - 2012/7

N2 - Induced pluripotent stem (iPS) cells can be established via forced epigenetic reprogramming of various somatic cells and selection based on given criteria. Human iPS cells are preferred for clinical applications because they present fewer ethical concerns than embryonic stem cells. However, technical issues of stability and safety must be fully validated before clinical use. Moreover, heart regenerative therapies would require approximately 109 cardiomyocytes per person, necessitating the following technical considerations: (1) genetically and epigenetically stable scaling up of the iPS cells, (2) efficient and reproducible differentiation, and (3) highly reliable cell purification. Furthermore, (4) strategies for efficient iPS transplantation, rapid maturation, and functional integration of grafted cardiomyocytes into the host myocardium are critical unmet technologies. Herein, we discuss current progress and unmet problems for the realization of heart regenerative therapy.

AB - Induced pluripotent stem (iPS) cells can be established via forced epigenetic reprogramming of various somatic cells and selection based on given criteria. Human iPS cells are preferred for clinical applications because they present fewer ethical concerns than embryonic stem cells. However, technical issues of stability and safety must be fully validated before clinical use. Moreover, heart regenerative therapies would require approximately 109 cardiomyocytes per person, necessitating the following technical considerations: (1) genetically and epigenetically stable scaling up of the iPS cells, (2) efficient and reproducible differentiation, and (3) highly reliable cell purification. Furthermore, (4) strategies for efficient iPS transplantation, rapid maturation, and functional integration of grafted cardiomyocytes into the host myocardium are critical unmet technologies. Herein, we discuss current progress and unmet problems for the realization of heart regenerative therapy.

UR - http://www.scopus.com/inward/record.url?scp=84863103779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863103779&partnerID=8YFLogxK

U2 - 10.1016/j.trre.2011.09.003

DO - 10.1016/j.trre.2011.09.003

M3 - Article

C2 - 22172453

AN - SCOPUS:84863103779

VL - 26

SP - 223

EP - 232

JO - Transplantation Reviews

JF - Transplantation Reviews

SN - 0955-470X

IS - 3

ER -